FemPulse Corporation
Darrin Uecker has held significant leadership roles in the biomedical and technology sectors, currently serving as Chief Technology Officer and President/CEO of Pulse Biosciences, Inc. since September 2015, and as an Advisory Board Member for FemPulse Corporation since June 2015. Previously, Uecker was President and Chief Operating Officer at Progyny (formerly Auxogyn, Inc.) from January 2014 to September 2015, and President/CEO of Gynesonics, Inc. from June 2009 to December 2013. Additional experience includes serving as EVP of Research, Development and Operations at CyberHeart, EVP R&D and Operations at Conceptus, and CTO at RITA Medical Systems, which was acquired for $220 million. Uecker began a notable career at Computer Motion, Inc. as CTO, a company later acquired by Intuitive Surgical. Uecker holds a Master of Science degree in Electrical and Computer Engineering from UC Santa Barbara.
This person is not in the org chart
This person is not in any teams
FemPulse Corporation
Overactive bladder (OAB) affects over 15 million women in the US. The sudden, urgent desire to pass urine greatly limits quality of life. Current treatments are not optimal, requiring frequent, time-consuming office visits, awkward vaginal probes, medications with potential side effects or surgery. Those suffering with OAB often consider the therapies too cumbersome and forgo treatment, opting instead to place limits on their life to accommodate the symptoms. Neuromodulation for OAB involving electrical stimulation of the sacral nerve is a proven and established therapy. However, despite being commercially available for over a decade only a small fraction of indicated patients have been treated. The cost and invasiveness of the surgery are often cited as concerns by prospective recipients. FemPulse has developed a novel, wearable medical device designed to deliver neuromodulation therapy directly to the nerves that regulate bladder function, without the need for surgical implant. The small device is easily placed by the patient herself and controlled with a smartphone app. The company is currently conducting clinical evaluations in the United States.